Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Zhu, Hong-Hu  [Clear All Filters]
2015
Zhang X-H, Wang G-X, Zhu H-H, Liu Y-R, Xu L-P, Han W, Chen H, Chen Y-H, Wang F-R, Wang J-Z, et al. Recruitment of CD8(+) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1(+) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2015.
2020
Qian J-J, Hu X, Wang Y, Zhang Y, Du J, Yang M, Tong H, Bin Qian W-, Wei J, Yu W, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. Cancer Med. 2020.
2022
Cheng W-Y, Li J-F, Zhu Y-M, Lin X-J, Wen L-J, Zhang F, Zhang Y-L, Zhao M, Fang H, Wang S-Y, et al. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(49):e2211429119.
Wang H, Mao L, Yang M, Qian P, Lu H, Tong H, Xie W, Zhou D, Huang X, Wang Y, et al. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022.
2023
Xie M, Shi T, Jiang Q, Jia Y, Zhou D, Tong H, Jin J, Zhu H-H. Chemotherapy with the use of next-generation TKIs based on MRD has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2023.
2024
Xiong Z-Y, Shen Y-J, Zhang S-Z, Zhu H-H. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens. Hematology. 2024;29(1):2335856.